trending Market Intelligence /marketintelligence/en/news-insights/trending/7ryhdllkzqfi0zzpz-grxq2 content esgSubNav
In This List

Kiadis Pharma launches private placement to fund blood cancer drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Kiadis Pharma launches private placement to fund blood cancer drug

Kiadis Pharma NV launched a private placement of about 2.6 million new shares to institutional investors.

The share sales represent about 14.8% of the Amsterdam-based company's current issued share capital.

The developer of therapies for blood disorders will announce the number of shares placed and the subscription price for the placing on March 13.

Kiadis Pharma intends to use the net proceeds of the placing to fund the development of its blood cancer drug ATIR101 as well as for expenses and general corporate purposes.

Jefferies International Ltd. is acting as sole book runner, Canaccord Genuity Ltd. as lead manager, Chardan as co-lead manager and LifeSci Capital LLC as co-manager in connection with the placement.

Saola Healthcare Partners is acting as financial adviser to the company.